EvoPAR-Breast01
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- NCT06380751 ↗
- Recruiting
- AstraZeneca
- Focused
We haven't built an HCP commentary report on EvoPAR-Breast01 (saruparib (AZD5305) plus camizestrant; camizestrant; saruparib (AZD5305) in first-line BRCA1/BRCA2/PALB2-mutated HR-positive, HER2-negative advanced breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EvoPAR-Breast01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 4 | |
| X threads | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- Saruparib (AZD5305); Camizestrant; Abemaciclib; Ribociclib; Palbociclib; Fulvestrant; Letrozole; Anastrozole; Exemestane
- Arms
- Arm 1: saruparib (AZD5305) plus camizestrant · Experimental
- Arm 2: Physician's choice CDK4/6i plus physician's choice ET · Active comparator
- Arm 3: Physician's choice CDK4/6i plus camizestrant · Experimental
- Arm 4: Saruparib (AZD5305) plus physician's choice ET · Experimental
- Enrollment
- 788 (estimated)
- Primary outcomes
- Progression-Free Survival (Arm 1 vs arm 2)
- Sponsor
- AstraZeneca
- Start
- Aug 1, 2024
- Primary completion
- Dec 18, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06380751 · updated Sep 2, 2026